Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Clinico-epidemiological Profile of Facial Dermatoses at a Teaching Hospital in Eastern India.

Annals of African medicine·2026

Same author

Omalizumab: a broader role in dermatology? Evidence and the road ahead.

Italian journal of dermatology and venereology·2025

Same author

Revisiting risankizumab: a newer biologic drug in dermatology.

Italian journal of dermatology and venereology·2024

Same author

Comparison of the clinical efficacy of topical tretinoin 0.05% cream and tacrolimus 0.1% ointment plus iontophoresis in the management of palmoplantar psoriasis.

Clinical and experimental dermatology·2024

Same author

Saxophone penis: A sequel to penoscrotal hidradenitis suppurativa.

Indian journal of sexually transmitted diseases and AIDS·2023

Same author

Giant Solitary Trichoepithelioma: A Diagnosis of Exclusion.

International journal of trichology·2023

Search research articles

Related Experiment Video

Updated: Jul 23, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Guselkumab - In Psoriasis and Beyond.

Aditya Kumar Bubna¹, Vinayak Viplav¹

¹Department of Dermatology, Katihar Medical College, Karim Bagh, Katihar, Bihar, India.

Dermatology Practical & Conceptual

|August 9, 2024

Summary

Guselkumab, an interleukin-23p19 inhibitor, effectively treats psoriasis and shows promise for other skin conditions, including rare cancers like Stewart-Treves angiosarcoma, with a good safety profile.

Area of Science:

Dermatology
Immunology
Oncology

Background:

Guselkumab is the first approved interleukin-23p19 inhibitor for moderate to severe psoriasis.
Its therapeutic value extends beyond psoriasis to various dermatologic conditions.

Purpose of the Study:

To review the efficacy of guselkumab in psoriasis management.
To explore its applications in off-label dermatologic disorders.

Main Methods:

A narrative review of studies was conducted.
Literature search performed on PubMed, Google Scholar, Scopus, and ResearchGate.
Keywords used: "Guselkumab", "Psoriasis", and "other dermatological disorders".

Main Results:

Guselkumab is effective for psoriasis and psoriatic arthropathy.

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Related Experiment Videos

Last Updated: Jul 23, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Successful use in hidradenitis suppurativa, lichen planus, pityriasis rubra pilaris, and pyoderma gangrenosum.

Emerging utility in Stewart-Treves angiosarcoma (STA).

Conclusions:

Guselkumab's benefits encompass numerous dermatologic conditions beyond psoriasis.
Potential applications in oncology, particularly for STA, warrant further investigation.
Guselkumab demonstrates an acceptable safety profile.